STOCK TITAN
  1. Home
  2. News
  3. GRTS

Gritstone bio, Inc. - GRTS STOCK NEWS

Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.

Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:

• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations

Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.

News

Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) is adjusting the timeline for the Phase 2b trial of its next-generation COVID-19 vaccine to Fall 2024 to incorporate fully GMP-grade raw materials, enhancing regulatory value and study interpretability. The company aims to address the latest seasonal variant and express gratitude to FDA and BARDA for their support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the granting of nonqualified stock options to six employees to purchase 147,000 shares of its common stock. The options have an exercise price of $2.26 and will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
News

Gritstone bio to Participate in Upcoming Investor Conference

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced their participation in B. Riley Securities' 4th Annual Oncology Conference. The event will feature a fireside chat with Andrew Allen, Co-founder, President, and CEO, discussing the company's work in developing potent vaccines. The webcast will be available live and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio, a clinical-stage biotechnology company (Nasdaq: GRTS), granted two employees nonqualified stock options to purchase 18,500 shares of its common stock at an exercise price of $2.10. The options will vest over a four-year period, subject to the employees’ continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options to four employees to purchase 42,000 shares of its common stock at an exercise price of $1.53, in line with Nasdaq Listing Rule 5635(c)(4). The options will vest over a four-year period, with 25% vesting on the first anniversary of hire, and 1/48th vesting monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
News

Gritstone bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) will be participating in investor conferences, including the 6th Annual Evercore ISI HealthCONx Conference, 35th Annual Piper Sandler Healthcare Conference, and First Annual Goldman Sachs Catalyst Clinic. The company's Co-founder, President, and CEO, Andrew Allen, M.D., Ph.D., will be speaking at these events. Live webcasts will be available via https://ir.gritstonebio.com/investors/events, with archived replays accessible for 30 days after each event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
News

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Rhea-AI Summary
Gritstone Bio, Inc. (Nasdaq: GRTS) reports financial results for Q3 2023 and recent updates on its COVID-19 prevention and cancer vaccine programs. The company has received a BARDA contract for a Phase 2b study comparing its samRNA vaccine candidate to an approved COVID-19 vaccine. Preliminary data from Phase 2 of its GRANITE cancer vaccine study are expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
earnings
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces grant of nonqualified stock options to new employee, part of inducement to join, with exercise price of $1.83 and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
none
-
News

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

Rhea-AI Summary
Gritstone bio presents results from Phase 1 studies of its self-amplifying mRNA vaccine candidates against COVID-19 at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
covid-19
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio grants stock options to employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
Stock GRTS logo
Gritstone bio, Inc.

Nasdaq:GRTS

GRTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GRTS Stock Data

3.80M
118.11M
1.91%
29.03%
6.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE